阻塞性睡眠呼吸暂停 低呼吸综合征和血管病变:我们目前所知道的最新情况
Zhenyu Mao1, Pengdou Zheng1, Xiaoyan Zhu1
1Department of Respiratory and Critical Care Medicine, National Health Committee (NHC) Key Laboratory of Respiratory Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
阻塞性睡眠呼吸暂停-呼吸暂停综合征 (OSAHS) 通过内皮功能障碍和炎症等机制引起血管病变. 本综述详细介绍了多个器官系统的OSAHS诱导的血管损伤,并讨论了治疗策略.
科学领域:
- 心血管和脑血管研究.
- 睡眠的药物 睡眠的药物
- 血管病理学 血管病理学
背景情况:
- 阻塞性睡眠呼吸暂停-呼吸暂停综合征 (OSAHS) 是一种常见的睡眠障碍,与严重的心血管和脑血管问题有关.
- 在OSAHS中间歇性缺氧是驱动血管损伤和位器官衰竭的关键因素.
- 血管病变是OSAHS病理生理学的核心,并代表着重大的公共卫生问题.
研究的目的:
- 综合审查OSAHS诱导血管病变的微观病理生理机制.
- 探索OSAHS对心血管,脑血管,视网膜,脏和生殖系统的血管健康的影响.
- 讨论目前的治疗策略,以减轻与OSAHS相关的血管并发症.
主要方法:
- 文献综述侧重于OSAHS诱导的血管病变的病理生理机制.
- 分析证据,将OSAHS与各种器官系统的血管损伤联系起来.
- 检查流行病学数据,风险因素和治疗进展.
主要成果:
- OSAHS通过内皮屏障破坏,代谢失调,炎症,氧化应激和表观遗传变化诱导血管病变.
- 有证据表明,心脏,大脑,眼睛,脏和生殖器官中的OSAHS相关的血管病理.
- 目前的研究突出了针对OSAHS诱导的血管损伤的各种治疗方法.
结论:
- 通过复杂的病理生理路径,OSAHS显著导致广泛的血管病变.
- 了解这些机制对于开发有效治疗OSAHS患者至关重要.
- 针对与OSAHS相关的血管损伤提供了改善患者结果和公共健康的潜力.
更多相关视频
04:53Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach
Published on: October 18, 2024
08:35Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
相关概念视频
Sleep Apnea
The condition is more prevalent among...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Hyperpnea and Hyperventilation
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
